Access Treatment

Pathway to Treatment

We have embedded quality in every step in our pathway from application submission to presentation of clinical data. We are industrializing the treatment of nano-rare patients by assuring that each step is of the upmost quality possible by bringing knowledge, technical expertise, high quality systems and processes together for each and every patient program.

Industralizing
the treatment of nano-rare

At n-Lorem, our mission is to treat the patients we can today. By working closely with our research physicians and their institutions, we discover, develop and provide personalized experimental ASO medicines to nano-rare patients for free, for life. This journey begins with a research physician submitting an application to treat for their patient to n-Lorem.

Preliminary Steps

Click on any step
for more details
1
Seek a diagnosis
2
Application for treatment is submitted
3
ATTC reviews application & makes a recommendation
4
n-Lorem approves application

Pathway to Treatment

Important:
Every mutation and every patient program is different. That means that some programs may move very rapidly, some may require a great deal of work, and unfortunately some may not be successful. Our timeline noted below is what we hope to achieve.

15-18 months

Estimated timeframe for ASO development before patient begins treatment

Find out if you
qualify for treatment

Before your research physician submits an application, review our qualifications to see if you meet the criteria for treatment.

We cannot do
this alone

Together we are changing the world—
one patient at a time

We hope that you join us on this journey to discover, develop and provide individualized antisense medicines for free for life for nano-rare patients. The ultimate personalized medicine approach – for free, for life.

We need your support

Join us on our Corps of Discovery of the mind and heart. Help us bring hope and potential help to nano-rare patients today. For free, for life.
Donate

Follow us on social for updates on our latest efforts